Janssen
FDA expands J&J Zytiga combo’s indication to include castration-sensitive prostate cancer
February 9, 2018Medical Communications, Sales and Marketing Cancer, FDA, J&J, JJ, Janssen, Johnson & Johnson, Zytiga, pharma
Johnson & Johnson has announced that Zytiga (abiraterone acetate) in combination with prednisone has been awarded FDA approval in the …
NICE meets Janssen halfway over Darzalex
January 18, 2018Medical Communications, Sales and Marketing J&J, JJ, Janssen, biotech, darzalex, drugs, pharma, pharmaceutical
NICE rejected Janssen’s Darzalex (Daratumumab) back in March last year, concluding that it wasn’t able to accurately determine the efficacy …
Novartis debuts new data showing Cosentyx’s superiority over Janssen’s Stelara in psoriasis
January 16, 2018Manufacturing and Production, Research and Development Cosentyx, Janssen, Novartis, Stelara, pharma
Novartis has lifted the curtain on new data comparing the efficacy of Cosentyx (secukinumab) to Janssen’s Stelara (ustekinumab) in achieving …
J&J’s Darzalex cuts risk of disease progression and death by 50%, new study shows
December 13, 2017Research and Development Genmab, J&J, JJ, Janssen, Johnson & Johnson, darzalex, multiple myeloma, pharma
Johnson and Johnson has revealed data which demonstrates that Darzalex (daratumumab), when combined with a regimen of bortezomib, melphalan and …
Partnerships hold the key to making HIV history
November 20, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing HIV, Janssen, pharma
Brian Woodfall, Global Head of Late Development, Infectious Diseases at Janssen, explains why a future without HIV can only be …
Janssen’s Stelara shows improvement in Crohn’s symptoms within one week, new findings reveal
October 30, 2017Manufacturing and Production, Research and Development Crohn’s disease, Janssen, Stelara, crohn's disease, pharma
Janssen has unveiled new data on Stelara (ustekinumab) in the treatment of patients with moderately to severely active Crohn’s disease …
J&J’s third quarter: The good and the bad
October 18, 2017Medical Communications, Research and Development, Sales and Marketing J&J, JJ, Janssen, Johnson & Johnson, biotech, drugs, pharma, pharmaceutical
It was a mixed bag for Johnson & Johnson on its announcement of third quarter results. It could largely be …
FDA expands Janssen’s Stelara to cover adolescent psoriasis patients
October 16, 2017Sales and Marketing FDA, Janssen, Stelara, pharma, psoriasis
Janssen has announced that the FDA has approved an expanded indication for its psoriasis therapy Stelara (ustekinumab) for the treatment …
Bayer forced to halt huge study into key drug
October 6, 2017Medical Communications, Research and Development Bayer, Janssen, Xarelto, biotech, drugs, pharma, pharmaceutical
Bayer, and development partner Janssen, have been forced to stop a Phase 3 trial looking at expanding the indication of …
Janssen reveals positive CHMP opinion, long-term data for psoriasis drug guselkumab
September 19, 2017Manufacturing and Production, Research and Development, Sales and Marketing EMA< CHMP, Janssen, guselkumab, pharma, pharmaceuticals
Janssen has announced that its psoriasis drug guselkumab has been awarded a positive opinion by the EMA’s Committee for Medicinal …
Janssen opposes use of its drug in state execution
August 23, 2017Medical Communications, Research and Development, Sales and Marketing Janssen, etomidate, life sciences, pharma, pharmaceutical
Janssen has spoken out against plans to use an anaesthetic drug it invented over 50 years ago to execute prisoners, …
Scientists discover ‘Achilles’ heel’ of oesophageal cancer
August 23, 2017Research and Development ICR, Janssen, biotech, drugs, pharma, pharmaceutical
Researchers from The Institute of Cancer Research have potentially found a new use for Imbruvica, after discovering a weakness in …
FDA turns down Janssen’s sirukumab for rheumatoid arthritis
August 3, 2017Sales and Marketing FDA, Janssen, drugs, life sciences, medicine, pharma, pharmaceuticals, rheumatoid arthritis, sirukumab
Janssen has announced that it has suffered a knockback to its plans to commercialise sirukumab in the US in the …
Janssen single tablet regimen shows Phase 3 success in HIV
July 26, 2017Research and Development HIV, Janssen, biotech, healthcare, pharma, pharmaceuticals
The latest Phase 3 data investigating Janssen’s darunivir in the treatment of human immunodeficiency virus (HIV-1) showed that the drug …
Monthly injectable HIV treatment proves as effective as traditional daily pill regimen
July 24, 2017Research and Development, Sales and Marketing AIDS, HIV, Janssen, ViiV Healthcare, biotech, drugs, pharma, pharmaceuticals
New early trial data suggests that current daily HIV pill regimens could be replaced with injections which slowly release medication …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
